Urinary Bladder
-
(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
-
(157-17) FID-007 in Treating Participants With Advanced Solid Tumors
-
(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
- (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
- (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer
- (188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors
-
(201-19) A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40
Antibody in Subjects with Advanced Solid Tumors
- (205-19) Study to Assess AFM24 in Advanced Solid Cancers
- (221-19) Study of GNX102 in Patients With Advanced Solid Tumors
- (230-19) A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination
With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- (231-19) QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus
Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG
Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.